Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

MyndYou Teams up with Mizuho Information & Research Institute to Detect Changes in Cognitive Function in Senior Adults in Japan

Published

on

Reading Time: 2 minutes

The Digital Health company MyndYou recently secured its Seed round of
financing from Howard L. Morgan, Amplifyher Ventures, Female Founders
Fund, Impact 1st and more.

NEW YORK–(BUSINESS WIRE)–#AI–MyndYou and Mizuho Information & Research Institute (MHIR) have entered
into a partnership agreement to conduct a joint PoC in the Japanese
Market to improve quality of life and prolong independence of senior
adults. The companies aim to commercialize the service by the end of
FY2019.

MHIR will leverage MyndYou’s Artificial Intelligence (AI) platform,
which passively detects changes in cognitive function of individuals
through voice. The platform then delivers actionable insights to care
providers. MyndYou’s full solution allows for detection of changes in
cognitive function through passive tracking of voice and additional
parameters such as walking, driving and daily activities.

This partnership is announced on the heels of MyndYou’s Seed financing
round, led by Howard L. Morgan, with participation by Amplifyher
Ventures, Female Founders Fund and additional investors. MyndYou’s Seed
round brings its financing to-date to $2.1 Million.

The company entered the US market last year and is expanding services to
Physician Practices, ACOs, Home Health Companies and Rehabilitation
Companies.

“As a growing NY-based company with proprietary technology developed in
Tel Aviv, we have partnered with MHIR to further the global potential
for MyndYou,” says Ruth Polikaine, CEO of MyndYou. “Now, the senior
adult population in Japan will have access to a technology that can not
only reduce readmission rates, but also prolong their independence,
while providing them with personalized, data-driven remote care.”

“The number of dementia patients in Japan has reached 4.62 million and
is expected to increase even further to seven million, which equals to
one in five seniors over 65, in 2025. The disease has become an
important problem not only for the medical field but also for the entire
Japanese society※1. As in many cases, individuals with
dementia receive the diagnosis only after the symptoms have progressed.
Making a diagnosis and providing adequate care in the early stage is
necessary.” says Hitoshi Morio, Joint General Manager, Innovation &
Strategy Division, Mizuho Information & Research.
“However, the
number of opportunities to grasp changes in cognitive function in the
early stage has declined with the increase of single- person households
and the decrease of chances to interact with others. We see a big
opportunity to change that through the partnership with MyndYou.”

※1 ”White Paper on Aging Society/ 2016” by the
Cabinet of Japan

About MHIR
With IT as its core
technology, Mizuho Information & Research Institute, Inc. (MHIR) is a
professional organization with approximately 4,700 employees that
provides assistance to corporations in increasing their corporate value
through consulting, system integration and outsourcing services. Our
consulting services provide high-quality solutions to customers, with
experts in four distinct fields looking one step into the future:
socioeconomics, telecommunications, environmental energy and science.
MHIR
is one of core group companies of Mizuho Financial Group.

About MyndYou
The MyndYou artificial
intelligence (AI) platform was designed to revolutionize
cognitive-driven care. Through groundbreaking analytics of speech and
day-to-day activity patterns of older adults collected through remote
care sessions and a seamless monitoring app, MyndYou detects subtle
changes in cognitive functioning that activates care adjustments and
timely interventions. With passive and continuous monitoring, AI-driven
actionable insights, and seamless integration into today’s care methods,
MyndYou empowers clinicians to deliver personalized care that
revolutionizes patient engagement, reduces healthcare costs, and
improves quality of life.

Contacts

For inquiries, please contact:
Ruth Poliakine
CEO
MyndYou
[email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

transfer

IMC to transfer its Oranim Pharmacy shares back to the seller

Published

on

imc-to-transfer-its-oranim-pharmacy-shares-back-to-the-seller

TORONTO and GLIL YAM, Israel, April 16, 2024 /PRNewswire/ — IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the “Company” or “IMC“), a leading medical cannabis company with operations in Israel and Germany, is announcing that, further to the news release dated January 12, 2024, the Company has decided not to make remaining installment payments installments (i.e. NIS 5,873K including interest or 2,154K CAD) by IMC Holdings Ltd., and as such will transfer the 51% shares held by IMC Holdings Ltd back to the  seller.

“With the April 1st cannabis legalization in Germany, we are focusing our resources on the German market, where we expect to see the biggest growth potential,” said Oren Shuster, CEO of IMC. “With both of our core markets, Germany and Israel, currently undergoing rapid evolution, we need to assure that we allocate our resources to the growth opportunities where we expect the best return on investment.”

About IM Cannabis Corp.

IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has recently exited operations in Canada to pivot its focus and resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC’s products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. Until recently, the Company also actively operated in Canada through Trichome Financial Corp and its wholly owned subsidiaries, where it cultivated, processed, packaged, and sold premium and ultra-premium cannabis at its own facilities under the WAGNERS and Highland Grow brands for the adult-use market in Canada. The Company has exited operations in Canada and considers these operations discontinued.

Disclaimer for Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements under applicable Canadian and U.S. securities laws (collectively, “forward-looking statements”). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to,  the occurrence of growth opportunities and the likelihood of growth potential.

Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the development and introduction of new products; continuing demand for medical and adult-use recreational cannabis in the markets in which the Company operates; the Company’s ability to reach patients through both e-commerce and brick and mortar retail operations; the Company’s ability to maintain and renew or obtain required licenses; the effectiveness of its products for medical cannabis patients and recreational consumers; and the Company’s ability to market its brands and services successfully to its anticipated customers and medical cannabis patients.

The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward looking statements due to a number of factors and risks. These include: any failure of the Company to maintain “de facto” control over Focus Medical in accordance with IFRS 10; the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the effect of the reform on the Company; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and Focus Medical (collectively, the “Group”) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt and war, conflict and civil unrest in Eastern Europe and the Middle East

Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made.

The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Company Contacts:

Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]

Oren Shuster, Chief Executive Officer
IM Cannabis Corp.
[email protected]

Logo – https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/imc-to-transfer-its-oranim-pharmacy-shares-back-to-the-seller-302117984.html

Continue Reading

Cannabis

Right on Brands Announces Major Product Line Expansion via HONEY® Brands

Published

on

Continue Reading

CCELL®

CCELL Launches Environmentally Conscious Eco Star AIO Vaporizer

Published

on

ccell-launches-environmentally-conscious-eco-star-aio-vaporizer

SHENZHEN, China, April 15, 2024 /PRNewswire/ — CCELL®, the world’s leading technology brand focused on creating trendsetting vape hardware products and advanced vaporization technology, today announced the launch of the Eco Star, the company’s all-in-one vaporizer focused on sustainability, wide-ranging oil compatibility, and ease of use.

The Eco Star’s casing material is made of biodegradable and plant-based PLA, a material that can be decomposed by bacteria or other living organisms. By adopting this type of eco-friendly casing, CCELL seeks to provide an option that can reduce the cannabis industry’s overall environmental impact and build a more sustainable society.

Built within the casing is a removable and recyclable lithium-ion battery. This thoughtful pull-apart design allows consumers to easily remove the battery before disposing of the casing, empowering them to contribute towards a greener Earth.

The Eco Star also features complete compatibility with all types of cannabis oils, clog-free dual air vents, and an isolated airway that ensures the cleanest possible vapor.

With increasing environmental challenges worldwide and tightening regulations on vape products, the Eco Star was introduced with the intention of raising environmental awareness across the industry.

The company has also implemented other measures to align its practices with its long-standing sustainability-focused values. These include offering biodegradable and plant-based PLA mouthpieces among its customization options. Additionally, the company uses energy-efficient aqueous processing in producing its patented ceramic heating cores to reduce greenhouse gas emissions.

Before the product’s official launch, CCELL provided their customers and consumers with an early look at the Eco Star at TPE24 and Hall of Flowers Ventura in the US, and Spannabis Barcelona in Spain.

Disclaimer for battery disposal: CCELL does not recycle lithium-ion batteries. Battery recycling requirements may vary by country, city, etc. Please contact your local recycling center for more details before disposal.

About CCELL®

CCELL® is a technology brand and global innovator in the portable vaporizer space that revolutionized the industry by introducing the ceramic heating component. CCELL® was born in the headquarters of Shenzhen Smoore Technology Limited, which has more than 10 years of expertise in the vaporization industry. With advanced R&D resources, patented technologies, strong production capabilities, and reliable quality control systems, CCELL® is recognized around the world for its exceptional vaporization technology and top-quality devices.

Learn more about CCELL® at www.ccell.com as well as on LinkedIn, Instagram, Facebook, Twitter, and YouTube.

Photo – https://mma.prnewswire.com/media/2386481/CCELL_Launches_Environmentally_Conscious_Eco_Star_AIO_Vaporizer.jpg
Logo – https://mma.prnewswire.com/media/2265752/CCELL_Logo_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/ccell-launches-environmentally-conscious-eco-star-aio-vaporizer-302116454.html

Continue Reading

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania